A research hospital



IRCCS Ospedale San Raffaele is a university hospital and scientific institute established in 1971 to provide specialized care for the most complex health conditions and to perform cutting-edge translational research. Ospedale San Raffaele was first recognized by the Italian Ministry of Health as a research hospital Ospedale San Raffaele in numbers vert(Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS) in 1972 for its expertise in diabetes research and cure. The recognition as IRCCS was then extended to the entire field of molecular medicine in 2001.

Ospedale San Raffaele in numbers vert Thanks to 100 high-tech laboratories and pre-clinical facilities, 50 medical specialties, 50.000 hospitalizations per year and more than 880 ongoing clinical trials, at Ospedale San Raffaele basic science translate quickly into clinical practice and clinical needs drive basic research.

Since May 2012, Ospedale San Raffaele joined Gruppo Ospedaliero San Donato, the leading Italian hospital group.


Forming tomorrow's doctors and researchers

Within OSR campus there is Università Vita-Salute San Raffaele, a university offering degrees in Biomedicine, Psychology and Philosophy. Each faculty includes undergraduate and graduate courses, research centers, doctoral schools and masters. Many university students – studying physiotherapy, nursing, medicine and biotechnology courses – can do their practical training in the hospital facilities: clinical departments and research labs.


A translational approach

IRCCS Ospedale San Raffaele integrates basic and clinical research through a translational approach, in which lab discoveries translate quickly into clinical therapies and clinical needs drive basic research. The institute aims at understanding the mechanisms underlying a variety of human diseases and at identifying new targets and therapeutic strategies to treat them. Among the principal clinical area of investigation: central and peripheral nervous systems pathologies, tumors, immuno-mediated, infectious, genetic, cardiovascular and metabolic diseases. 

Alongside with improving therapies, the institute seeks to develop new technologies in the field of genomics and imaging, needed for early diagnosis and personalized cures. The Institute is recognized as a global authority in cell and gene therapies, and is at the forefront of research in many other field.


Institutional leadership

President: Paolo Rotelli

Vice President: Kamel Ghribi

CEO: Marco Centenari

Chief Medical Officer: Roberts Mazzuconi

Research Director: Anna Flavia d'Amelio Einaudi

Scientific Director: Prof. Gianvito Martino

Deputy Scientific Director: Prof. Luca Guidotti

Deputy Scientific Director: Prof. Antonio Esposito